Follow Rsvvw'19 live!

We are happy to announce that RSVVW2019 conference can be followed live through our website. Please click on the button below to see and hear us live on 12 - 14 Nov. 
On 12- 14 November 2019 ReSViNET Foundation will host its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!

Symposium on
​RSV Epidemiology and surveillance

You are invited to join the symposium - The goal of the symposium is to provide an overview of various ongoing RSV molecular epidemiology and surveillance studies and to summarize key research questions, strategies, data, and updates from these RSV molecular surveillance programs and work towards harmonizing approaches and analyses.

PAPER OF THE MONTH - November 2019

RSV/NS2/1313/I1314L vaccine in RSV-seronegative children is safe and immunogenic
Ruth A. Karron,1 Cindy Luongo,2 Jocelyn San Mateo,1 Kimberli Wanionek,1 Peter L. Collins,2 Ursula J. Buchholz,2 and the RSVPed Team

The RSV/NS2/1313/I1314L is an intranasal vaccine that contains two attenuating elements in the RSV strain: deletion of the NS2 gene and deletion of the codon 1313. The deletions are stabilized with the substitution of isoleucine at codon 1314. This vaccine induced an immunogenic response in nonhuman primates. A phase 1 double-blind, randomized, placebo-controlled trial was conducted at the Center for Immunization Research (CIR) between 2013 and 2018 in RSV-seronegative and RSV-seropositive children aged 12-59 months. RSV-seronegative children received a single dose of 10 5 or 10 6 PFU and RSV-seropositive children received a single dose of 10 6 PFU. The authors demonstrated that none of the RSV-seropositive children had a ≥4-fold rise in RSV F serum IgG titer. By contrast, 53% of RSV-seronegative children who received 10 5 PFU, developed RSV neutralizing antibodies and F
IgG responses. In RSV-seronegative children receiving 10 6 PFU, even 80% developed RSV neutralizing antibodies and a similar rise in RSV-F IgG antibodies. This indicates that the RSV vaccine is a proper and genetically stable candidate in RSV-seronegative children, which deserves further clinical evaluation in seronegative children.

This review was written by Safia Laqqa under the supervision of Louis Bont

Out now: RESVINET T-SHIRTs

Order a ReSViNET T-Shirt and
​contribute to our research.
Neeltje from The Netherlands, 99 years old, participant of the RESCEU Older adults study. RSV is an important cause of pneumonia in older adults. Awareness of RSV in older adults is almost absent. Every year about 3-6% of all older adults are infected with RSV. Course of disease is most severe on older adults with severe underlying disease such as heart failure or COPD.
​
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.

ABOUT RESVINET FOUNDATION

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.

ReSViNET Global partners